CeGaT and the Future of Genetic Sequencing

Season 4 of Glioblastoma aka GBM kicks off Brain Tumor Awareness Month with a closer look at CeGaT, a genetic diagnostics company based in Tübingen, Germany. Founded in 2009 by Dr. Saskia Biskup and Dirk Biskup, CeGaT focuses on identifying rare diseases and tumor-specific mutations through advanced sequencing technologies. In this episode, we speak with Dr. Biskup and Florian Battke, Head of Research & Development, about what genetic sequencing is, how it’s used in the context of brain tumors, and what they see as the next frontier for diagnosing and treating diseases like glioblastoma. We discuss how long-read sequencing may offer greater accuracy in identifying genetic changes and what that could mean for patients navigating difficult diagnoses. This episode explores the broader role that genomics can play in brain cancer research and the questions still left to answer as science continues to evolve. To learn more about the work CeGaT is doing, visit them online at https://cegat.com/ This episode is intended for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for guidance specific to your health or treatment plan.